Published Tue, 16 Jun 2020 13:45:31 -0400 on Seeking Alpha
VIG holds a portfolio of large-cap and giant-cap dividend growth stocks with at least 10 consecutive years of dividend growth.
Stocks in VIG's portfolio should perform well in a post-COVID-19 world as they have better balance sheets and competitive positions than their smaller peers.
VIG is trading at an expensive valuation compared to their historical average.
More than a year ago, I have written an article to analyze Vanguard Dividend Appreciation Index Fund ETF (VIG). I feel it is time for me to evaluate the outlook of VIG again. VIG tracks the Nasdaq U.S. Dividend Achievers Select Index. The fund owns U.S. stocks that have at least 10 years of dividend growth. Most of VIG's stocks are large-cap and giant-cap stocks that have better balance sheets and competitive positions than their smaller peers and should survive and thrive in a post-COVID-19 world. However, these stocks are quite expensive right now. Hence, we think investors may want to wait on the sidelines.
Data by YCharts
A portfolio of giant and large-cap stocks
VIG's portfolio currently includes 225 dividend stocks that have been growing their dividend consistently. Most of the stocks in VIG's portfolio are giant-cap and large-cap stocks. In fact, giant-cap and large-cap stocks represent about 52.2% and 36.2% of VIG's portfolio respectively.
I like VIG's exposure to large-cap and giant-cap stocks because these stocks generally have better balance sheets than their medium and smaller peers. This is important because the outbreak of COVID-19 will have the potential to last for several years unless an effective vaccine is developed quickly, which may take 1 to 2 years from now. Therefore, it is less risky to invest in large and giant-cap stocks. As an article written by The New York Times says,
What you saw in '08, '09 were the companies that were able to continue to invest came out the other side and actually accelerated... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|JOHNSON & JOHNSON||130.43||21.6||6.03||3.80||2.93|
|PROCTER & GAMBLE||122.77||90.3||1.36||2.98||2.49|
Older articles featuring Johnson & Johnson (JNJ):Retirement Strategy: An Obvious Future Dividend Aristocrat, But It Is Too Expensive To Buy Right Now
Merck: Amazing Oncology Division, Underwhelming Dividend Opportunity
Is Target Corporation’s Dividend Hike a Surprise to Income Investors?
My Dividend Growth Portfolio Half Time Report: 38 Holdings, 1 Buy, 3 Sells
Q2 2020 Dividend Report
Introducing The Dividend Growth 30
64 Reliable Stocks Raising Dividends 40 Years Or More: July's Update
Top 10 Healthcare Stocks For Dividend Growth And Income
Nicholas Ward's Dividend Growth Portfolio: June 2020 Update
Retirement Strategy: The Pandemic Is Still Here, So Is Dividend Growth Investing So Let's Update 'PRIP'